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Brief statement: High mobility group box 1 (HMGB-1) has been associated with inflammation and 19 
atherosclerosis, which results in elevated HMGB-1 levels in patients with abdominal aortic aneurysms 20 
(AAA) because aneurysms contain a large amount of atherosclerotic tissue. There are no data regarding 21 
changes in HMGB-1 levels following surgical interventions for AAA. We investigated the serum HMGB-22 
1 levels before and after either endovascular aortic repair (EVAR) or open aortic repair (OAR). The 23 
serum HMGB-1 was higher in patients with AAA than in controls. However, the elevated HMGB-1 24 
2 
levels normalized after graft replacement or stent placement for AAA. This is the first report describing 25 
changes in serum HMGB-1 after surgical treatment of AAA.   26 
3 
Abstract 27 
Objectives: High-mobility group box 1 (HMGB-1) is a key substance mediating inflammation 28 
and development of atherosclerotic lesions (AL), including abdominal aortic aneurysms (AAA). 29 
Serum levels of HMGB-1 are increased in patients with AAA than in normal controls because 30 
the ALs in AAAs secrete HMGB-1. We therefore postulate that the serum HMGB-1 level should 31 
decrease after endovascular aortic repair (EVAR) or open aortic repair (OAR). However, there is 32 
no evidence of this in the literature. The purpose of this study was to investigate the changes in 33 
HMGB-1 levels after surgical intervention for AAA. We also aimed to determine if the HMGB-1 34 
levels varied between the two procedures. 35 
Design: Prospective study. 36 
Materials and methods: Serum HMGB-1 levels were determined in 24 patients with AAA and 37 
25 healthy controls. Twelve of the 24 AAA patients underwent EVAR while the other half 38 
underwent OAR. The relationship between HMGB-1 levels and presence of AAA or influence of 39 
operative methods on the serum HMGB-1 level were prospectively investigated. 40 
Results: Serum HMGB-1 levels in AAA patients were significantly higher than in healthy 41 
controls (9.4 ± 5.7 vs. 4.1 ± 2.0 ng/mL, P < 0.01). The serum HMGB-1 levels in both the EVAR 42 
group and the OAR group were significantly decreased from baseline at both 3 months and 1 43 
year after surgery.  44 
Conclusions: Removal or isolation of AL via surgical intervention significantly decreases serum 45 
HMGB-1 levels. The significant post-operative reduction in HMGB-1 levels suggests that 46 
important endocrinological changes occur after surgical treatment of AAA. 47 
Key Words: Abdominal aortic aneurysm, Atherosclerosis, Covered stenting, High-mobility 48 
group box 1   49 
4 
Introduction 50 
     High-mobility group box 1 (HMGB-1) is a nonhistone DNA-binding protein consisting of 51 
215 amino acid residues organized into 3 domains that include 2 tandem HMGB domains (A box 52 
and B box) arranged in an L-shape configuration and a 30 amino acid long C-terminal tail.1, 2 53 
HMGB-1 functions as an intracellular regulator of gene transcription and promotes secretion of 54 
several inflammatory cytokines including interleukin (IL), tumor necrosis factor (TNF)–α, γ-55 
interferon, and macrophage inflammatory proteins-1α and -1β.3,4,5,6 HMGB-1 is therefore 56 
regarded as a key mediator of inflammation-related responses, including inflammation, tissue 57 
regeneration, cancer, infections, and development of atherosclerotic lesions (AL), including 58 
abdominal aortic aneurysms (AAA).5  59 
     Elevated HMGB-1 expression has been detected in ALs in endothelial cells, vascular smooth 60 
muscle cells, and macrophages.7 Increased HMGB-1 expression leads to progression of ALs and 61 
may result in development of AAAs. The ALs in AAAs then secrete more HMGB-1, further 62 
accelerating growth of the AAAs.8,9 There are two surgical treatments for AAA: open aortic 63 
repair (OAR) and endovascular aortic repair (EVAR). In patients with AAA, serum HMGB-1 is 64 
increased compared to that in normal controls,8 probably because ALs in AAAs secrete HMGB-65 
1. Therefore, theoretically, the serum HMGB-1 level will decrease after OAR or EVAR because 66 
these procedures result in a large amount of the AL in the AAA being removed or isolated from 67 
the patient’s blood circulation. However, there is no published evidence supporting this. The 68 
purpose of this study was to investigate the changes in HMGB-1 secretion after surgical 69 
intervention for AAA. 70 
 71 
Materials and Methods  72 
5 
Patients 73 
     Figure 1 shows the study design. We enrolled 49 subjects, consisting of 24 AAA patients and 74 
25 healthy volunteers. All 24 AAA patients underwent surgical interventions—12 underwent an 75 
OAR using a Dacron graft (the AL was removed from the blood circulation) and the other 12 76 
underwent EVAR (the AL was isolated from the blood circulation). There was no endoleak after 77 
EVAR. The serum HMGB-1 levels were measured at baseline in all participants and were not 78 
repeated in the control group. In the AAA group, serum HMGB-1 levels were repeated at 3 79 
months and 1 year after surgery. All patients and volunteers gave informed consent, and the 80 
study was approved by the Institutional Review Board at Okayama University Hospital 81 
(Okayama, Japan). 82 
 83 
Measurements 84 
     Blood samples were collected in the conventional manner and centrifuged (3000 rpm, 10 min) 85 
to obtain serum, which was stored at –80ºC. The concentration of HMGB-1 in serum samples 86 
was determined using an enzyme-linked immunosorbent assay kit according to the 87 
manufacturer’s protocol (Shino-Test, Sagamihara, Japan). We analyzed cell counts and 88 
biochemistry using standard methods established by the Department of the Central Clinical 89 
Laboratory, Okayama University Hospital. 90 
 91 
Statistical Analysis 92 
     The characteristics of the AAA group and the control group were compared and the 93 
difference in serum HMGB-1 levels at baseline between the two groups was analyzed. Baseline 94 
serum HMGB-1 levels were compared against levels obtained at 3 months and l year post 95 
6 
surgery. Comparisons were also made between the EVAR and OAR groups to investigate the 96 
effect of the different surgical procedures on the serum levels of HMGB-1. All data were 97 
expressed as mean ± SEM or SD. The Mann-Whitney U test was used to analyze differences 98 
between the quantitative data in the AAA and control groups. The chi-square test was used for 99 
analysis of the categorical variables. Time-course variation of serum HMGB-1 levels from their 100 
preoperative values to the values 1 year post intervention between the OAR and EVAR groups 101 
were tested using 2-way ANOVA. A probability value of < 0.05 was considered to be 102 
statistically significant. Statistical analyses were performed with IBM SPSS software, version 103 
19.0.0 (SPSS Inc., Chicago, Illinois). 104 
 105 
Results 106 
Baseline characteristics of all patients 107 
     The baseline demographic and clinical characteristics of the AAA patients and controls are 108 
shown in Table I. The AAA group had significantly higher pulse wave velocity than the control 109 
group. Smoking, diabetes, and hyperlipidemia were more prevalent in the AAA group than in the 110 
control group.  111 
     Table II shows the laboratory data for the entire patient cohort. The AAA group had 112 
significantly higher levels of fibrinogen degradation products and D-dimer, and lower levels of 113 
hemoglobin, activated partial thromboplastin time, albumin, and high-density lipoprotein (HDL) 114 
cholesterol than the control group. Serum HMGB-1 levels were significantly higher in the AAA 115 
group than in the control group (Figure 2). 116 
 117 
Time-course variations in HMGB-1 after vascular surgery 118 
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     All patients in the AAA group survived surgery and were well 1-year post intervention with 119 
no major complications. Serum HMGB-1 levels were significantly decreased after surgical 120 
intervention (Figure 3). Both OAR and EVAR significantly decreased serum HMGB-1 levels at 121 
3 months and 1 year after the surgery (Figure 4-A,B). In addition, 2-way ANOVA analysis 122 
showed that there were no significant differences in the degree of reduction in serum HMGB-1 123 
levels between the OAR group and the EVAR group 1 year after intervention (Figure 4-C). 124 
 125 
Discussion 126 
     This study showed significantly increased serum HMGB-1 levels in AAA patients than in 127 
controls. These results are consistent with previous reports that HMGB-1 expression is enhanced 128 
in all layers of the aortic wall, including atheromatous lesions in AAA patients,3 and that plasma 129 
HMGB-1 levels are increased in AAA patients.8 The results of this study confirmed the 130 
relationship between increased serum HMGB-1 levels and the presence of AAA. 131 
     This study is the first to demonstrate a significant reduction in serum HMGB-1 levels in AAA 132 
patients after surgical intervention with similar reductions seen after either OAR or EVAR. The 133 
postulated reason for this phenomenon is that a large amount of HMGB-1 secreting AL was 134 
removed or isolated from the blood circulation by graft replacement or covered-stent placement. 135 
A previous study showed that HMGB-1 was highly expressed in inflammatory cells in the 136 
adventitia, media, and atherosclerotic plaques. HMGB-1 was also expressed in smooth muscle 137 
cells and endothelial cells in AAA tissue.3 In this study, there is a possibility that the remaining 138 
aortic wall may continue to secret HMGB1 after EVAR or after graft replacement and the 139 
secreted HMGB1 will enter the circulation via the remaining vasa vasorum. However, the 140 
decrease of HMGB1 after AAA surgery was significant. In addition, the only difference between 141 
8 
pre- and post-operative conditions in the patients was removal or isolation of the atherosclerotic 142 
plaque. Furthermore, there were no cases of endoleak after EVAR in this study. These results 143 
suggest that the main cause of HMGB1 increase in patients with AAA was secretion from the 144 
atherosclerotic plaque in AAA, not from the aortic wall itself. 145 
     The long-term outcome of decreased HMGB-1 could not be determined from this study. Our 146 
observations indicate that the eventual post-operative reduction in serum HMGB-1 is not related 147 
to adverse outcomes in terms of immediate survival or incidence of major post-surgical 148 
complications. The decreased HMGB-1 levels following surgical treatment of AAA clearly 149 
demonstrate that these interventions trigger an important endocrinological change, which 150 
suggests surgical intervention is likely to have a significant impact in terms of long-term 151 
outcomes. In a study using a transgenic mouse model, reduction of inflammatory cytokines, 152 
including HMGB-1, was shown to reduce the development of atherosclerotic changes.10 153 
Therefore, decreased HMGB-1 levels after surgery for AAA may have beneficial effects for 154 
long-term vascular outcomes. Further study is necessary to determine if this is truly the case. 155 
 156 
Study Limitations 157 
     This study was limited by the relatively small number of patients. 158 
 159 
Conclusion 160 
     The baseline serum HMGB-1 levels were significantly increased in the AAA group compared 161 
to those in the control group. The HMGB-1 levels in AAA patients significantly decreased after 162 
OAR or EVAR. Removal or isolation of large AL may suppress progression of atherosclerotic 163 
disease due to the decreased secretion of HMBG-1 after intervention. Further studies are required 164 
9 
to determine whether decreased HMBG-1 levels truly improve outcomes of atherosclerotic 165 
vascular diseases. 166 
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Table I. Baseline demographic and clinical characteristics of all patients 232 
  Control (n = 25) AAA (n = 24) p value 
Male % (n) 56.0 (14) 73.6 (18) 0.28 
Age (years) 69.8 ± 5.3 71.8 ± 6.7 0.2 
BMI 24.1 ± 3.8 23.2 ± 4.0 0.15 
Systolic blood pressure (mmHg) 122.4 ± 16.7 130.1 ± 19.7 0.13 
Diastolic blood pressure (mmHg) 75.5 ± 9.1 73.7 ± 11.6 0.87 
ABI (right) 1.18 ± 0.11 1.08 ± 0.13 0.67 
ABI (left) 1.15 ± 0.13 1.05 ± 0.18 0.62 
PWV (right) (cm/s) 1547 ± 366 2089 ± 481 < 0.01 
PWV (left) (cm/s) 1540 ± 370 2022 ± 488 0.02 
Smoker % (n) 8.0 (2) 24.0 (10)  0.01 
Medication 
   
Hypertension % (n) 48.0 (12) 58.5 (14) 0.18 
Diabetes % (n) 0 29.2 (7)) 0.01 
Hyperlipidemia % (n) 24.0 (6) 62.5 (15)  < 0.01 
Data are shown as mean ± SD (or percentage and number). AAA; abdominal aortic aneurysm, ABI; ankle 233 
branch index, BMI; body mass index, PWV; pulse wave velocity. 234 
 235 
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Table II. Baseline laboratory based parameters of all subjects 236 
Laboratory values control (n = 25) AAA (n = 24) p value 
WBC × 104 (/μL) 6.2 ± 2.7 5.9 ± 1.6 0.70 
Hb (mg/dl) 13.7 ± 2.0 12.6 ± 1.7 0.03 
Hct (%) 40.0 ± 5.1 37.8 ± 4.6 0.08 
Plt × 104 (/μL) 212 ± 46 224 ± 86 0.45 
APTT (sec) 113 ± 18 102 ± 26 0.048 
Fibrinogen (mg/dl) 396 ± 127 487 ± 204 0.16 
FDP (μg/ml) 4.8 ± 1.8 16.7 ± 14.3 0.03 
D-dimer (ng/ml) 1.5 ± 1.0 8.3 ± 7.0 0.03 
TP (g/dL) 7.1 ± 0.5 7.1 ± 0.5 0.87 
Albumin (g/dL) 4.2 ± 0.3 3.9 ± 0.5 0.01 
Creatinine (mg/dL)  1.3 ± 1.2 1.0 ± 1.2 0.94 
T-chol (mg/dL) 194 ± 27 192 ± 38 0.78 
HDL-chol (mg/dL) 67.8 ± 15.1 49.5 ± 10.8 < 0.01 
HbA1c (%) 5.8 ± 0.4 5.9 ± 0.5 0.47 
BNP (pg/mL) 31.6 ± 57.5 54.5 ± 62.8 0.29 
CRP (mg/dL) 0.5 ± 0.9 2.2 ± 4.8 0.14 
HMGB-1 (ng/ml) 4.1 ± 2.0 9.4 ± 5.7 < 0.01 
Data are shown as mean ± SD. AAA; abdominal aortic aneurysm, APTT; activated partial thromboplastin 237 
time, BNP; brain natriuretic peptide, CRP; C-reactive protein, FDP; fibrinogen degradation products, Hb; 238 
hemoglobin, Hct; hematocrit, HDL-chol; high-density lipoprotein-cholesterol, HMGB-1, high-mobility 239 
group box 1, Plt; platelet, T-chol; total cholesterol, TP; total protein, WBC; white blood cell.  240 
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Figure legends 241 
Figure 1. Tree diagram of patients enrolled in this study 242 
AAA; abdominal aortic aneurysm, EVAR; endovascular aortic repair, HMGB-1; high-mobility 243 
group box 1, OAR; open aortic repair 244 
 245 
Figure 2. Serum HMGB-1 levels before intervention 246 
The serum HMGB-1 level was higher at baseline in the AAA group than in the control group. All 247 
data are expressed as mean ± SEM. *P < 0.01, AAA vs. control group. 248 
 249 
Figure 3. Time course variance of changes in HMGB-1 levels after surgical intervention for 250 
AAA 251 
Following intervention, the AAA patients showed decreased serum HMGB-1 levels on follow up 252 
at 3 months and 1 year compared to baseline. All data are expressed as mean ± SEM. *P < 0.01, 253 
3 months or 1 year vs. baseline. 254 
 255 
Figure 4. Changes in serum HMGB-1 levels after EVAR or OAR 256 
The serum HMGB-1 levels decreased after surgery in both EVAR and OAR groups at 3 months 257 
and 1 year follow-up compared with baseline (A, B). No significant differences in post-surgical 258 
HMGB-1 levels were observed between the two groups (C). *P < 0.05, baseline vs. 3 months, 259 
**P < 0.01, baseline vs. 1 year. EVAR; endovascular aortic repair, OAR; open aortic repair. 260 
 261 
 262 
 263 
15 
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Figure 2. Serum HMGB-1 levels before intervention 274 
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Figure 3. Time course variance of changes in HMGB-1 levels after surgical intervention for AAA 286 
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Figure 4. Changes in serum HMGB-1 levels after EVAR or OAR 297 
 298 
